Latest News - Glaukos Corporation

Wednesday, June 21, 2017 | Clinical Trials, Glaucoma, Glaukos Corporation

Study: Combining Implantation of Glaukos iStent inject with Topical Travoprost Provides Sustained IOP Reduction and Favorable Safety Profile

Glaukos announced that a study of 53 open-angle glaucoma subjects recently published in Clinical & Experimental Ophthalmology showed that the iStent inject Trabecular Micro-Bypass, combined with t…

Read the full story

Tuesday, May 23, 2017 | Medical Studies, Glaukos Corporation

Study Reveals Potential Cost Efficiency of Using Two Glaukos iStent Trabecular Micro-Bypass Stents to Treat Elevated IOP

Glaukos announced that an analysis published in the Journal of Medical Economics evaluating various options for treating elevated IOP in open-angle glaucoma patients showed that two iStent Trabecular …

Read the full story

Wednesday, May 03, 2017 | Clinical Trials, Glaukos Corporation

Glaukos Completes Patient Enrollment in Phase II Clinical Trial for iDose Travoprost Intraocular Implant in Glaucoma Patients

Glaukos Corporation announced the completion of patient enrollment in the investigational new drug (IND) phase 2 study of its Travoprost intraocular implant with the iDose delivery system in patients …

Read the full story

Friday, April 14, 2017 | Medical Studies, Glaukos Corporation

International Study Shows Two Glaukos iStent Trabecular Micro-Bypass Stents and One Topical Medication Deliver Sustained IOP Reduction

Glaukos announced that a study published in Clinical Ophthalmology showed that two iStent Trabecular Micro-Bypass Stents and one topical ocular hypotensive medication achieved a 38% reduction in mean …

Read the full story

Thursday, April 13, 2017 | Acquisitions/Mergers, Glaucoma, Glaukos Corporation, MIGS

Glaukos Corporation Acquires IOP Sensor System from DOSE Medical

Glaukos announced that it has acquired the IOP sensor system assets and related liabilities from DOSE Medical Corporation for $5.5 million in cash, plus performance-based consideration of up to $9.5 m…

Read the full story

Thursday, March 16, 2017 | Glaucoma, Glaukos Corporation, MIGS

Glaukos Announces Five-Year Extensions for Three Category III CPT Codes Related to Microinvasive Glaucoma Surgery

Glaukos announced that the Current Procedural Terminology (CPT) Editorial Panel of the American Medical Association has granted 5-year extensions to three Category III CPT codes that describe insertio…

Read the full story

Wednesday, February 22, 2017 | Management/Leadership, Glaukos Corporation

L. Jay Katz, MD, Joins Glaukos Corporation as Chief Medical Officer

Glaukos announced that L. Jay Katz, MD, FACS, has joined the company as Chief Medical Officer. Dr. Katz is currently a practicing ophthalmologist, the Director of Glaucoma Service at Wills Eye Hospita…

Read the full story

Thursday, February 16, 2017 | Clinical Trials, Glaukos Corporation, MIGS

Glaukos Completes Patient Enrollment in Pivital Phase of US IDE Clinical Trial for iStent Supra

Glaukos announced the completion of patient enrollment in the pivotal phase of its FDA investigational device exemption (IDE) trial for the iStent Supra Suprachoroidal Micro-Bypass Stent. The iSten…

Read the full story

Monday, February 06, 2017 | Management/Leadership, Glaukos Corporation

Joseph Gilliam to Join Glaukos Corporation as Chief Financial Officer and Senior Vice President of Corporate Development

Glaukos announced that Joseph E. Gilliam will join the company as Chief Financial Officer and Senior Vice President, Corporate Development in May 2017. Mr. Gilliam will replace the company’s cur…

Read the full story

Thursday, February 02, 2017 | Management/Leadership, Glaukos Corporation

Glaukos Corporation Promotes Chris M. Calcaterra to Chief Operating Officer

Glaukos Corporation announced that Chris M. Calcaterra has been named Chief Operating Officer, effective immediately. Mr. Calcaterra joined Glaukos in 2008 and has served as its Chief Commercial Offic…

Read the full story

Monday, December 12, 2016 | Glaucoma, Medical Studies, Glaukos Corporation

Study Published in Journal of Glaucoma Evaluates a Single Glaukos iStent Trabecular Micro-Bypass Stent as a Standalone Procedure

Glaukos Corporation announced that a study published recently in the Journal of Glaucoma showed that a single iStent Trabecular Micro-Bypass Stent significantly reduced IOP when implanted as a standal…

Read the full story

Tuesday, November 08, 2016 | Clinical Trials, Glaucoma, Medical Studies, Glaukos Corporation, MIGS

New International Study Highlights IOP-Lowering Performance of Glaukos iStent inject Trabecular Micro-Bypass in Standalone Procedure

Glaukos announced that in a study published in Advances in Therapy, 100% of 57 phakic eyes with open angle glaucoma achieved a ≥ 20% reduction in unmedicated IOP 1 year after implantation of the iS…

Read the full story

Monday, October 31, 2016 | Clinical Trials, Glaucoma, Glaukos Corporation, MIGS

Report: iStent Trabecular Micro-Bypass Stent Reduced IOP and Medication Use in Predominately Hispanic Glaucoma Patient Population

Glaukos Corporation announced that a study of 134 predominantly Hispanic eyes with open-angle glaucoma (OAG), published in Clinical Ophthalmology, showed mean IOP of 12.9 mm Hg and a 61% decrease in m…

Read the full story

Tuesday, September 27, 2016 | Glaucoma, Medical Studies, Glaukos Corporation, MIGS

New Study Underscores Ability of iStent to Achieve Sustained Reductions in IOP and Medication Use

A study published in Clinical Ophthalmology showed that a consistent cohort of 107 open-angle glaucoma (OAG) eyes receiving the iStent Trabecular Micro-Bypass Stent in combination with cataract surger…

Read the full story

Friday, September 23, 2016 | Glaucoma, Medical Studies, Glaukos Corporation, MIGS

International Study Shows Favorable 3-Year Results of 2 Glaukos iStent Trabecular Micro-Bypass Stents as Initial Treatment for Naïve Glaucoma

Glaukos announced that an international study published in Ophthalmology and Therapy showed that newly diagnosed primary open-angle glaucoma patients achieved a 43% reduction in mean IOP to 14.6 mm Hg…

Read the full story
Load More